<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326102</url>
  </required_header>
  <id_info>
    <org_study_id>107CS-6</org_study_id>
    <nct_id>NCT03326102</nct_id>
  </id_info>
  <brief_title>PK, Efficacy and Safety Study of DHP107 in Patients With Recurrent or Metastatic Breast Cancer</brief_title>
  <acronym>OPERA</acronym>
  <official_title>A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daehwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daehwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of
      DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients
      with Recurrent or Metastatic Breast Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be assigned to DHP107 or IV paclitaxel in a ratio of 2:1 (n=48 to DHP107 and n=24 to IV paclitaxel)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>Every 8 weeks upto 18 months from randomization date</time_frame>
    <description>ORR is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>PFS is defined as the time from date of randomization until the date of first documented progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Up to 36 months from FPI</time_frame>
    <description>OS is defined as the time from the date of inclusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure(TTF)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>TTF is defined as the time from the randomization date to the date of discontinuation of treatment, regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>DOR is the time between the initial response to therapy and subsequent disease progression or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>DCR is defined as the percentage of subjects who were evaluated for complete response(CR), partial response(PR), and stable disease(SD) as the best response among from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(QoL)</measure>
    <time_frame>after randomization(C1D1), D1 of every 3rd cycle(each cycle consists of 28 days) up to 18 months</time_frame>
    <description>Evaluate changes compared to baseline using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>on Day 1 of Cycle 1(each cycle consists of 28days) at predose, 1, 2, 3, 4, 6 and 10 hrs post dose (before the 2nd dose on Day 1) and on Day 8 of Cycle 1 at predose (before the 1st dose on Day 8)</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>on Day 1 of Cycle 1(each cycle consists of 28days) at predose, 1, 2, 3, 4, 6 and 10 hrs post dose (before the 2nd dose on Day 1) and on Day 8 of Cycle 1 at predose (before the 1st dose on Day 8)</time_frame>
    <description>Maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>on Day 1 of Cycle 1(each cycle consists of 28days) at predose, 1, 2, 3, 4, 6 and 10 hrs post dose (before the 2nd dose on Day 1) and on Day 8 of Cycle 1 at predose (before the 1st dose on Day 8)</time_frame>
    <description>Time to reach observed maximum concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Recurrent or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>DHP107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[Part 1] The first 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.
[Part 2] total 48 subjects (including part 1 subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[Part 2] 24 subject will receive IV paclitaxel 80 mg/m2 weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHP107</intervention_name>
    <description>DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days</description>
    <arm_group_label>DHP107</arm_group_label>
    <other_name>Liporaxel®, Oral Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Paclitaxel</intervention_name>
    <description>IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)</description>
    <arm_group_label>IV paclitaxel</arm_group_label>
    <other_name>Taxol Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are ≥18 years of age on the date of written informed consent.

          2. Subjects with confirmed diagnosis of recurrent or metastatic breast cancer based on
             histopathology examination

          3. Subjects with diagnosis of HER2-negative breast cancer that was confirmed by IHC or in
             situ hybridization (ISH) assessment of tumor samples

          4. Subjects who have received up to 3 lines of therapy for advanced disease, without
             prior exposure to taxane in the advanced stage setting

          5. Subjects who have a life expectancy of ≥12 weeks.

          6. Subjects who are able to take oral medication.

          7. Subjects who have a performance status of ≤2 on the Eastern Cooperative Oncology Group
             (ECOG) scale.

          8. Subjects who have measurable disease according to the Response Evaluation Criteria in
             Solid Tumors Version 1.1 (RECIST version 1.1).

          9. Subjects who have adequate organ functions

         10. Subjects who are willing and able to comply with scheduled visits, treatment plans,
             laboratory tests, and procedures.

         11. Subjects who have voluntarily agreed to participate by giving written informed
             consent.

         12. Women of childbearing potential who have negative pregnancy test results

        Exclusion Criteria:

          1. Subjects who have history of severe hypersensitive reaction to the active ingredient
             or any excipients of DHP107 or IV paclitaxel.

          2. Subjects who have received prior taxane therapy in the metastatic setting

          3. Subjects whose adjuvant or neoadjuvant treatment for early stage breast cancer was
             completed within 6 months prior to entry into the study.

          4. Subjects who received radiation therapy within 2 weeks of randomization (C1D1)

          5. Subjects who were diagnosed with New York Heart Association (NYHA) Class II congestive
             heart failure or have clinically significant arrhythmia not controlled by medication
             prior to study entry.

          6. Subjects who developed cardiovascular disease within 24 weeks prior to study entry,
             which is deemed to be clinically significant by the Investigator.

          7. Subjects with known active hepatitis B or C infection, or hepatobiliary disease, or
             known history of immunodeficiency virus infection.

          8. Subjects with neuropathy grade ≥2 based on CTCAE v4.03 at the time of study entry

          9. Subjects with uncontrolled medical or mental illness that, in the Investigator's
             judgement, could affect treatment tolerability or compliance.

         10. Subjects diagnosed with other malignant primary tumor

         11. Subjects with symptomatic, untreated metastases to the central nervous system (CNS) at
             the time of screening.

         12. Subjects who are currently receiving prescription or non prescription medications or
             other products known to be moderate or potent inhibitors/inducers of CYP3A4, P-gp, or
             CYP2C8.

         13. Subjects who cannot tolerate oral administration as determined by the Investigator

         14. Pregnant or breastfeeding women.

         15. Subjects who have received any investigational drugs or devices within 4 weeks before
             the first day of study treatment (C1D1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope Rugo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vidula Neelima, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital(MGK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bora Lim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Priyanka Sharma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center(KUCC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Pluard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Luke's Cancer Institute(SLCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hope Rugo, M.D.</last_name>
    <phone>415-353-7070</phone>
    <email>Hope.Rugo@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rugo Hope, M.D.</last_name>
      <phone>415-353-7070</phone>
      <email>Hope.Rugo@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute(SLCI)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Pluard, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center(KUCC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priyanka Sharma, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital(MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vidula Neelima, M.D.</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD anderson cancer center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bora Lim, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>DHP107</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Liporaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

